Plain Language Summary: Hereditary hemorrhagic telangiectasia (HHT) is a rare inherited bleeding disorder that has historically received less research attention than other bleeding conditions. Recent advances have led to new treatments that can reduce bleeding and anemia, creating new hope for patients. New research shows that HHT places a significant financial burden on patients and the healthcare system, with costs driven largely by chronic bleeding, anemia, blood transfusions, and iron treatments. Experts have also developed standardized definitions and outcome measures for HHT clinical trials, which will help researchers compare treatments, improve study quality, and speed the development of new therapies. The article calls for earlier diagnosis, better use of preventive care, and adoption of common research standards to improve outcomes and make care more cost-effective.
